150 related articles for article (PubMed ID: 33791203)
1. Systematic Evaluation for the Influences of the SOX17/Notch Receptor Family Members on Reversing Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells.
Du Z; Li L; Sun W; Zhu P; Cheng S; Yang X; Luo C; Yu X; Wu X
Front Oncol; 2021; 11():607291. PubMed ID: 33791203
[TBL] [Abstract][Full Text] [Related]
2. Knocking down SOX2 overcomes the resistance of prostate cancer to castration via notch signaling.
Du Z; Chen X; Zhu P; Lv Q; Yong J; Gu J
Mol Biol Rep; 2023 Nov; 50(11):9007-9017. PubMed ID: 37716921
[TBL] [Abstract][Full Text] [Related]
3. Loss of Notch1 Activity Inhibits Prostate Cancer Growth and Metastasis and Sensitizes Prostate Cancer Cells to Antiandrogen Therapies.
Rice MA; Hsu EC; Aslan M; Ghoochani A; Su A; Stoyanova T
Mol Cancer Ther; 2019 Jul; 18(7):1230-1242. PubMed ID: 31028097
[TBL] [Abstract][Full Text] [Related]
4. Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer.
Ojo D; Lin X; Wong N; Gu Y; Tang D
Cancers (Basel); 2015 Nov; 7(4):2290-308. PubMed ID: 26593949
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar T; Yang JC; Gao AC; Evans CP
Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
[TBL] [Abstract][Full Text] [Related]
6. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
7. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
Fujimoto N
J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
[TBL] [Abstract][Full Text] [Related]
8. Steroid hormone synthetic pathways in prostate cancer.
Mostaghel EA
Transl Androl Urol; 2013 Sep; 2(3):212-227. PubMed ID: 25379460
[TBL] [Abstract][Full Text] [Related]
9. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
11. Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions.
Tucci M; Zichi C; Buttigliero C; Vignani F; Scagliotti GV; Di Maio M
Onco Targets Ther; 2018; 11():7353-7368. PubMed ID: 30425524
[TBL] [Abstract][Full Text] [Related]
12. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
13. Role of Androgen Receptor in Prostate Cancer: A Review.
Fujita K; Nonomura N
World J Mens Health; 2019 Sep; 37(3):288-295. PubMed ID: 30209899
[TBL] [Abstract][Full Text] [Related]
14. Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer.
Lavaud P; Dumont C; Thibault C; Albiges L; Baciarello G; Colomba E; Flippot R; Fuerea A; Loriot Y; Fizazi K
Ther Adv Med Oncol; 2020; 12():1758835920978134. PubMed ID: 33488778
[TBL] [Abstract][Full Text] [Related]
15. [ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer].
Chen ZY; Dong Q; Liu LR; Wei Q
Zhonghua Nan Ke Xue; 2019 Feb; 25(2):172-176. PubMed ID: 32216207
[TBL] [Abstract][Full Text] [Related]
16. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
[TBL] [Abstract][Full Text] [Related]
17. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.
Stoyanova T; Riedinger M; Lin S; Faltermeier CM; Smith BA; Zhang KX; Going CC; Goldstein AS; Lee JK; Drake JM; Rice MA; Hsu EC; Nowroozizadeh B; Castor B; Orellana SY; Blum SM; Cheng D; Pienta KJ; Reiter RE; Pitteri SJ; Huang J; Witte ON
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6457-E6466. PubMed ID: 27694579
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
[TBL] [Abstract][Full Text] [Related]
19. CCN3-EZH2-AR feedback loop: new targets for enzalutamide and castration resistant prostate cancer.
Armstrong CM; Gao AC
J Cell Commun Signal; 2017 Mar; 11(1):89-91. PubMed ID: 28255661
[TBL] [Abstract][Full Text] [Related]
20. Metformin mitigates PLCε gene expression and modulates the Notch1/Hes and androgen receptor signaling pathways in castration-resistant prostate cancer xenograft models.
Li Q; Xu K; Tian J; Lu Z; Pu J
Oncol Lett; 2021 Oct; 22(4):715. PubMed ID: 34429755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
